BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Perrigo Company plc Reports Third Quarter 2016 Financial Results
November 10, 2016 1:56 AM ESTDUBLIN, Nov. 10, 2016 /PRNewswire/ --Â
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered third quarter reported net loss of $1.3 billion and reported diluted loss per share of $8.76, driven by goodwill impairment charge of $804Â million and brand intangible assets impairment charge of $866Â million; delivered third quarter reported gross margin of 37.4%, and third quarter reported operating margin of (111.8)% Realized adjusted net income of $236Â million and adjusted diluted earnings per share of $1.65; achieved third quarter adjusted gross margin of 47.5%... MorePerrigo Company Plc to Review Strategic Alternatives for Tysabri® Royalty Stream
November 10, 2016 1:56 AM ESTDUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO John T. Hendrickson stated, "We continue to make progress on and take action against our stated strategic and operational plans first outlined in April 2016. Tysabri® dramatically improves the quality of life of patients with multiple sclerosis and its... More
